Harish Shantharam
CIK 1976391 · Chief Financial Officer · last filed 2026-01-28
Harish Shantharam is a Chief Financial Officer who has filed 8 SEC Form 4 insider transactions across 2 companies since 2023. The most recent filing, for ALXO, was dated Jan 28, 2026. Across all open-market trades the lifetime net is +$58.4K, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $118.5K across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$118.5K
2
8
$58.4K
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ALXO | Chief Financial Officer | 75,000 | $1.58 | $118.5K | $58.4K | 5 | 2026-01-28 |
| CymaBay Therapeutics, Inc. (CBAY) Delisted | Chief Financial Officer | 0 | $32.48 | $0 | $0 | 3 | 2024-03-22 |
Recent Filings
8 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-01-28 | ALXO | Grant (A) | — | $0 | EDGAR |
| 2025-10-16 | ALXO | Grant (A) | — | $0 | EDGAR |
| 2025-08-20 | ALXO | Buy (P) | +75,000 | $58.4K | EDGAR |
| 2025-04-15 | ALXO | Grant (A) | — | $0 | EDGAR |
| 2025-01-23 | ALXO | Grant (A) | — | $0 | EDGAR |
| 2024-03-22 | CymaBay Therapeutics, Inc. (CBAY) Delisted | Disp (D) | −20,125 | $0 | EDGAR |
| 2024-01-26 | CymaBay Therapeutics, Inc. (CBAY) Delisted | Grant (A) | +20,125 | $0 | EDGAR |
| 2023-05-22 | CymaBay Therapeutics, Inc. (CBAY) Delisted | Grant (A) | — | $0 | EDGAR |